Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Roivant Sciences Ltd. or Vertex Pharmaceuticals Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest Biotechnology and Roivant Sciences Ltd., Vertex Pharmaceuticals Incorporated Stock News

As of December 11, 2025, Roivant Sciences Ltd. had a $14.8 billion market capitalization, compared to the Biotechnology median of $226.8 million. Roivant Sciences Ltd.’s stock is NA in 2025, NA in the previous five trading days and up 74.63% in the past year.

Currently, Roivant Sciences Ltd. does not have a price-earnings ratio. Roivant Sciences Ltd.’s trailing 12-month revenue is $20.3 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -64.4%. Analysts expect adjusted earnings to reach $-1.094 per share for the current fiscal year. Roivant Sciences Ltd. does not currently pay a dividend.

Currently, Vertex Pharmaceuticals Incorporated’s price-earnings ratio is 31.4. Vertex Pharmaceuticals Incorporated’s trailing 12-month revenue is $11.7 billion with a 31.3% net profit margin. Year-over-year quarterly sales growth most recently was 11.0%. Analysts expect adjusted earnings to reach $18.449 per share for the current fiscal year. Vertex Pharmaceuticals Incorporated does not currently pay a dividend.

How We Compare Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated Stock Value Grades

Company	Ticker	Value
Roivant Sciences Ltd.	ROIV	D
Vertex Pharmaceuticals Incorporated	VRTX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Roivant Sciences Ltd. has a Value Score of 33, which is Expensive. Vertex Pharmaceuticals Incorporated has a Value Score of 16, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Roivant Sciences Ltd. or Vertex Pharmaceuticals Incorporated has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Roivant Sciences Ltd. or Vertex Pharmaceuticals Incorporated is the better investment when it comes to value.

Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated’s Quality Grades

Company	Ticker	Quality
Roivant Sciences Ltd.	ROIV	C
Vertex Pharmaceuticals Incorporated	VRTX	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Roivant Sciences Ltd. has a Quality Score of 50, which is Average. Vertex Pharmaceuticals Incorporated has a Quality Score of 86, which is Very Strong.

The Quality Grade Winner: Vertex Pharmaceuticals Incorporated

As you can clearly see from the Quality Grade breakdown above, Vertex Pharmaceuticals Incorporated has a better overall quality grade than Roivant Sciences Ltd.. For investors who are looking for companies with higher quality than others in the same industry, Vertex Pharmaceuticals Incorporated could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated’s Momentum Grades

Company	Ticker	Momentum
Roivant Sciences Ltd.	ROIV	A
Vertex Pharmaceuticals Incorporated	VRTX	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Roivant Sciences Ltd. has a Momentum Score of 90, which is Very Strong. Vertex Pharmaceuticals Incorporated has a Momentum Score of 53, which is Average.

The Momentum Grade Winner: Roivant Sciences Ltd.

As you can clearly see from the Momentum Grade breakdown above, Roivant Sciences Ltd. is considered to have stronger momentum compared to Vertex Pharmaceuticals Incorporated. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Roivant Sciences Ltd. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated Grades

In addition to Value, Momentum and Quality, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Roivant Sciences Ltd. or Vertex Pharmaceuticals Incorporated Stock?

Overall, Roivant Sciences Ltd. stock has a Value Score of 33, Momentum Score of 90 and Quality Score of 50.

Vertex Pharmaceuticals Incorporated stock has a Value Score of 16, Momentum Score of 53 and Quality Score of 86.

Comparing Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.